Page 443 - شرور شركات الأدوية

‫ﻣﺼﺎدر اﻟﺼﻮر‬

(1-1) http://www.cochrane.org/about-us/history/our-logo%23files.
(1-2) Mulrow CD. Rationale for systematic reviews. BMJ. 1994 Sep

3;309(6954):597–9. Available at: http://www.ncbi.nlm.nih.gov/pmc/
articles/PMC2541393/?page=1;
(1-3) Ranibizumab and pegaptanib for the treatment of age- related
macular degeneration: a systematic review and economic evalua-
tion. NICE 2006. Available at: http://www.nice.org.uk/nicemedia/live/
11700/34991/34991.pdf.
(1-4) http://www.prescrire.org/editoriaux/EDI33693.pdf.
(3-1) Carpenter D. Reputation and Power: Organizational Image and Phar-
maceutical Regulation at the FDA. Princeton University Press, 2010.
(3-2) Schwartz LM, Woloshin S, Welch HG. Using a Drug Facts Box to Com-
municate Drug Benefits and Harms Two Randomized Trials. Ann In-
tern Med. 2009 Apr 21;150(8):516–27. Available at: http://dartmed
.dartmouth.edu/spring08/pdf/disc_drugs_we/lunesta_box.pdf.
(3-3) http://www.lunesta.com/PostedApprovedLabelingText.pdf.
(4-1) Lurie P, Wolfe SM. Misleading data analyses in salmeterol (SMART)
study. The Lancet. 2005 Oct;366(9493): 1261-2.